{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:39:21Z","timestamp":1792179561763,"version":"4.4.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T00:00:00Z","timestamp":1710806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T00:00:00Z","timestamp":1710806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"DOI":"10.1007\/s00404-024-07408-2","type":"journal-article","created":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T06:51:21Z","timestamp":1710831081000},"page":"2307-2313","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["PCOS phenotype focus: phenotype D under the magnifying glass"],"prefix":"10.1007","volume":"309","author":[{"given":"Samuel H.","family":"Myers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Montanino Oliva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Nordio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1805-3181","authenticated-orcid":false,"given":"Vittorio","family":"Unfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,19]]},"reference":[{"issue":"9","key":"7408_CR1","first-page":"89","volume":"7","author":"V Rodriguez Paris","year":"2019","unstructured":"Rodriguez Paris V, Bertoldo MJ (2019) The mechanism of androgen actions in PCOS etiology. Med Sci 7(9):89","journal-title":"Med Sci"},{"issue":"3","key":"7408_CR2","doi-asserted-by":"publisher","first-page":"e1071","DOI":"10.1210\/clinem\/dgaa839","volume":"106","author":"KM Hoeger","year":"2021","unstructured":"Hoeger KM, Dokras A, Piltonen T (2021) Update on PCOS: consequences, challenges, and guiding treatment. J Clin Endocrinol Metab 106(3):e1071\u2013e1083. https:\/\/doi.org\/10.1210\/clinem\/dgaa839","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"7408_CR3","doi-asserted-by":"publisher","first-page":"4237","DOI":"10.1210\/jc.2006-0178","volume":"91","author":"R Azziz","year":"2006","unstructured":"Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W et al (2006) Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 91(11):4237\u20134245. https:\/\/doi.org\/10.1210\/jc.2006-0178","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"7408_CR4","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.xfss.2020.12.007","volume":"2","author":"R Azziz","year":"2021","unstructured":"Azziz R (2021) How polycystic ovary syndrome came into its own. F S Sci 2(1):2\u201310. https:\/\/doi.org\/10.1016\/j.xfss.2020.12.007","journal-title":"F S Sci"},{"key":"7408_CR5","doi-asserted-by":"publisher","unstructured":"Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41\u20137. doi: https:\/\/doi.org\/10.1093\/humrep\/deh098.","DOI":"10.1093\/humrep\/deh098"},{"issue":"9","key":"7408_CR6","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1093\/humrep\/dey256","volume":"33","author":"HJ Teede","year":"2018","unstructured":"Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L et al (2018) Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome\u2020\u2021. Hum Reprod 33(9):1602\u20131618. https:\/\/doi.org\/10.1093\/humrep\/dey256","journal-title":"Hum Reprod"},{"issue":"4","key":"7408_CR7","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.fertnstert.2023.07.025","volume":"120","author":"HJ Teede","year":"2023","unstructured":"Teede HJ, Tay CT, Laven J, Dokras A, Moran LJ, Piltonen TT et al (2023) Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome\u2020. Fertil Steril 120(4):767\u2013793. https:\/\/doi.org\/10.1016\/j.fertnstert.2023.07.025","journal-title":"Fertil Steril"},{"issue":"2","key":"7408_CR8","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.fertnstert.2008.06.035","volume":"91","author":"R Azziz","year":"2009","unstructured":"Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W et al (2009) The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 91(2):456\u2013488. https:\/\/doi.org\/10.1016\/j.fertnstert.2008.06.035","journal-title":"Fertil Steril"},{"issue":"7","key":"7408_CR9","doi-asserted-by":"publisher","first-page":"6213","DOI":"10.3390\/ijms24076213","volume":"24","author":"V Unfer","year":"2023","unstructured":"Unfer V, Dinicola S, Russo M (2023) A PCOS paradox: does inositol therapy find a rationale in all the different phenotypes? Int J Mol Sci 24(7):6213. https:\/\/doi.org\/10.3390\/ijms24076213","journal-title":"Int J Mol Sci"},{"key":"7408_CR10","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.bpobgyn.2016.03.009","volume":"37","author":"D Dewailly","year":"2016","unstructured":"Dewailly D (2016) Diagnostic criteria for PCOS: is there a need for a rethink? Best Pract Res Clin Obstet Gynaecol 37:5\u201311. https:\/\/doi.org\/10.1016\/j.bpobgyn.2016.03.009","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"11","key":"7408_CR11","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1111\/jog.14097","volume":"45","author":"NT Cao","year":"2019","unstructured":"Cao NT, Le MT, Nguyen VQH, Pilgrim J, Le VNS, Le DD et al (2019) Defining polycystic ovary syndrome phenotype in Vietnamese women. J Obstet Gynaecol Res 45(11):2209\u20132219. https:\/\/doi.org\/10.1111\/jog.14097","journal-title":"J Obstet Gynaecol Res"},{"key":"7408_CR12","doi-asserted-by":"publisher","DOI":"10.5603\/GP.a2021.0239","author":"HJ Lee","year":"2022","unstructured":"Lee HJ, Jo HN, Noh HK, Kim SH, Joo JK (2022) Is there association between thyroid stimulating hormone levels and the four phenotypes in polycystic ovary syndrome? Ginekol Pol. https:\/\/doi.org\/10.5603\/GP.a2021.0239","journal-title":"Ginekol Pol"},{"key":"7408_CR13","unstructured":"Clinicaltrials.gov. www.clinicaltrials.gov Accessed 12\/06\/23."},{"key":"7408_CR14","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.coemr.2020.03.004","volume":"12","author":"S Mumusoglu","year":"2020","unstructured":"Mumusoglu S, Yildiz BO (2020) Polycystic ovary syndrome phenotypes and prevalence: differential impact of diagnostic criteria and clinical versus unselected population. Current Opinion in Endocrine and Metabolic Research 12:66\u201371. https:\/\/doi.org\/10.1016\/j.coemr.2020.03.004","journal-title":"Current Opinion in Endocrine and Metabolic Research"},{"issue":"2","key":"7408_CR15","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3109\/09513590.2015.1107895","volume":"32","author":"Y Zhao","year":"2016","unstructured":"Zhao Y, Ruan X, Mueck AO (2016) Clinical and laboratory indicators of polycystic ovary syndrome in Chinese Han nationality with different Rotterdam criteria-based phenotypes. Gynecol Endocrinol 32(2):151\u2013156. https:\/\/doi.org\/10.3109\/09513590.2015.1107895","journal-title":"Gynecol Endocrinol"},{"issue":"2","key":"7408_CR16","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00404-015-3889-5","volume":"293","author":"AS Jamil","year":"2016","unstructured":"Jamil AS, Alalaf SK, Al-Tawil NG, Al-Shawaf T (2016) Comparison of clinical and hormonal characteristics among four phenotypes of polycystic ovary syndrome based on the Rotterdam criteria. Arch Gynecol Obstet 293(2):447\u2013456. https:\/\/doi.org\/10.1007\/s00404-015-3889-5","journal-title":"Arch Gynecol Obstet"},{"issue":"5","key":"7408_CR17","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.fertnstert.2014.08.001","volume":"102","author":"NM Daan","year":"2014","unstructured":"Daan NM, Louwers YV, Koster MP, Eijkemans MJ, de Rijke YB, Lentjes EW et al (2014) Cardiovascular and metabolic profiles amongst different polycystic ovary syndrome phenotypes: who is really at risk? Fertil Steril 102(5):1444\u201351.e3. https:\/\/doi.org\/10.1016\/j.fertnstert.2014.08.001","journal-title":"Fertil Steril"},{"issue":"5","key":"7408_CR18","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.rbmo.2016.01.010","volume":"32","author":"F Ramezanali","year":"2016","unstructured":"Ramezanali F, Ashrafi M, Hemat M, Arabipoor A, Jalali S, Moini A (2016) Assisted reproductive outcomes in women with different polycystic ovary syndrome phenotypes: the predictive value of anti-M\u00fcllerian hormone. Reprod Biomed Online 32(5):503\u2013512. https:\/\/doi.org\/10.1016\/j.rbmo.2016.01.010","journal-title":"Reprod Biomed Online"},{"issue":"11","key":"7408_CR19","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1080\/09513590.2019.1613640","volume":"35","author":"M Gupta","year":"2019","unstructured":"Gupta M, Yadav R, Mahey R, Agrawal A, Upadhyay A, Malhotra N et al (2019) Correlation of body mass index (BMI), anti-mullerian hormone (AMH), and insulin resistance among different polycystic ovary syndrome (PCOS) phenotypes\u2014a cross-sectional study. Gynecol Endocrinol 35(11):970\u2013973. https:\/\/doi.org\/10.1080\/09513590.2019.1613640","journal-title":"Gynecol Endocrinol"},{"issue":"1","key":"7408_CR20","doi-asserted-by":"publisher","first-page":"42","DOI":"10.4103\/jhrs.jhrs_141_21","volume":"15","author":"A Khurana","year":"2022","unstructured":"Khurana A, Swamy MV, Mitra S, Srinivas S, Nagaraja N (2022) Prevalence of polycystic ovarian syndrome, phenotypes and their ovulation response to sequential Letrozole dose escalation among infertile women at a Tertiary Care Centre in Southern India. J Hum Reprod Sci 15(1):42\u201350. https:\/\/doi.org\/10.4103\/jhrs.jhrs_141_21","journal-title":"J Hum Reprod Sci"},{"issue":"6","key":"7408_CR21","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1016\/j.fertnstert.2014.02.020","volume":"101","author":"AL de Guevara","year":"2014","unstructured":"de Guevara AL, Fux-Otta C, Crisosto N, de Mereshian PS, Echibur\u00fa B, Iraci G et al (2014) Metabolic profile of the different phenotypes of polycystic ovary syndrome in two Latin American populations. Fertil Steril 101(6):1732\u20131739. https:\/\/doi.org\/10.1016\/j.fertnstert.2014.02.020","journal-title":"Fertil Steril"},{"issue":"11","key":"7408_CR22","doi-asserted-by":"publisher","first-page":"661","DOI":"10.5603\/GP.a2020.0122","volume":"91","author":"AC Ozay","year":"2020","unstructured":"Ozay AC, Emekc\u0131 Ozay O, Gulekli B (2020) Comparison of anti-m\u00fcllerian hormone (AMH) and hormonal assays for phenotypic classification of polycystic ovary syndrome. Ginekol Pol 91(11):661\u2013667. https:\/\/doi.org\/10.5603\/GP.a2020.0122","journal-title":"Ginekol Pol"},{"key":"7408_CR23","doi-asserted-by":"publisher","first-page":"440","DOI":"10.3389\/fendo.2020.00440","volume":"11","author":"A Adamska","year":"2020","unstructured":"Adamska A, \u0141ebkowska A, Krentowska A, Hryniewicka J, Adamski M, Le\u015bniewska M et al (2020) Ovarian reserve and serum concentration of thyroid peroxidase antibodies in euthyroid women with different polycystic ovary syndrome phenotypes. Front Endocrinol 11:440. https:\/\/doi.org\/10.3389\/fendo.2020.00440","journal-title":"Front Endocrinol"},{"issue":"3","key":"7408_CR24","doi-asserted-by":"publisher","first-page":"732","DOI":"10.3390\/jcm9030732","volume":"9","author":"AM Polak","year":"2020","unstructured":"Polak AM, Adamska A, Krentowska A, \u0141ebkowska A, Hryniewicka J, Adamski M et al (2020) Body composition, serum concentrations of androgens and insulin resistance in different polycystic ovary syndrome phenotypes. J Clin Med 9(3):732. https:\/\/doi.org\/10.3390\/jcm9030732","journal-title":"J Clin Med"},{"issue":"10","key":"7408_CR25","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.30351","volume":"14","author":"A Purwar","year":"2022","unstructured":"Purwar A, Nagpure S (2022) Insulin resistance in polycystic ovarian syndrome. Cureus 14(10):e30351. https:\/\/doi.org\/10.7759\/cureus.30351","journal-title":"Cureus"},{"issue":"12","key":"7408_CR26","doi-asserted-by":"publisher","first-page":"869","DOI":"10.3390\/metabo11120869","volume":"11","author":"W Chen","year":"2021","unstructured":"Chen W, Pang Y (2021) Metabolic syndrome and PCOS: pathogenesis and the role of metabolites. Metabolites 11(12):869. https:\/\/doi.org\/10.3390\/metabo11120869","journal-title":"Metabolites"},{"issue":"11","key":"7408_CR27","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.tem.2023.08.005","volume":"34","author":"SH Myers","year":"2023","unstructured":"Myers SH, Russo M, Dinicola S, Forte G, Unfer V (2023) Questioning PCOS phenotypes for reclassification and tailored therapy. Trends Endocrinol Metab 34(11):694\u2013703. https:\/\/doi.org\/10.1016\/j.tem.2023.08.005","journal-title":"Trends Endocrinol Metab"},{"key":"7408_CR28","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ejogrb.2018.02.031","volume":"224","author":"P Tripathy","year":"2018","unstructured":"Tripathy P, Sahu A, Sahu M, Nagy A (2018) Metabolic risk assessment of Indian women with polycystic ovarian syndrome in relation to four Rotterdam criteria based phenotypes. Eur J Obstet Gynecol Reprod Biol 224:60\u201365. https:\/\/doi.org\/10.1016\/j.ejogrb.2018.02.031","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"4","key":"7408_CR29","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1111\/cen.14063","volume":"91","author":"E Carmina","year":"2019","unstructured":"Carmina E, Nasrallah MP, Guastella E, Lobo RA (2019) Characterization of metabolic changes in the phenotypes of women with polycystic ovary syndrome in a large Mediterranean population from Sicily. Clin Endocrinol 91(4):553\u2013560. https:\/\/doi.org\/10.1111\/cen.14063","journal-title":"Clin Endocrinol"},{"issue":"10","key":"7408_CR30","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1093\/humrep\/deaa190","volume":"35","author":"S Mackens","year":"2020","unstructured":"Mackens S, Pareyn S, Drakopoulos P, Deckers T, Mostinckx L, Blockeel C et al (2020) Outcome of in-vitro oocyte maturation in patients with PCOS: does phenotype have an impact? Hum Reprod 35(10):2272\u20132279. https:\/\/doi.org\/10.1093\/humrep\/deaa190","journal-title":"Hum Reprod"},{"issue":"2 Pt 1","key":"7408_CR31","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1097\/aog.0b013e31823f7135","volume":"119","author":"E Carmina","year":"2012","unstructured":"Carmina E, Campagna AM, Lobo RA (2012) A 20-year follow-up of young women with polycystic ovary syndrome. Obstet Gynecol 119(2 Pt 1):263\u2013269. https:\/\/doi.org\/10.1097\/aog.0b013e31823f7135","journal-title":"Obstet Gynecol"},{"issue":"1","key":"7408_CR32","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1080\/09513590.2020.1775193","volume":"37","author":"A Bahadur","year":"2021","unstructured":"Bahadur A, Mundhra R, Kashibhatla J, Rajput R, Verma N, Kumawat M (2021) Prevalence of metabolic syndrome among women with different PCOS phenotypes\u2014a prospective study. Gynecol Endocrinol 37(1):21\u201325. https:\/\/doi.org\/10.1080\/09513590.2020.1775193","journal-title":"Gynecol Endocrinol"},{"issue":"2","key":"7408_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0246862","volume":"16","author":"R Dadachanji","year":"2021","unstructured":"Dadachanji R, Patil A, Joshi B, Mukherjee S (2021) Elucidating the impact of obesity on hormonal and metabolic perturbations in polycystic ovary syndrome phenotypes in Indian women. PLoS ONE 16(2):e0246862. https:\/\/doi.org\/10.1371\/journal.pone.0246862","journal-title":"PLoS ONE"},{"key":"7408_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.825528","volume":"13","author":"M Farhadi-Azar","year":"2022","unstructured":"Farhadi-Azar M, Behboudi-Gandevani S, Rahmati M, Mahboobifard F, Khalili Pouya E, Ramezani Tehrani F et al (2022) The prevalence of polycystic ovary syndrome, its phenotypes and cardio-metabolic features in a community sample of Iranian population: tehran lipid and glucose study. Front Endocrinol (Lausanne) 13:825528. https:\/\/doi.org\/10.3389\/fendo.2022.825528","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"7408_CR35","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1530\/eje-08-0797","volume":"160","author":"E Maratou","year":"2009","unstructured":"Maratou E, Hadjidakis DJ, Kollias A, Tsegka K, Peppa M, Alevizaki M et al (2009) Studies of insulin resistance in patients with clinical and subclinical hypothyroidism. Eur J Endocrinol 160(5):785\u2013790. https:\/\/doi.org\/10.1530\/eje-08-0797","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"7408_CR36","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1046\/j.1365-2265.1999.00719.x","volume":"50","author":"GE Krassas","year":"1999","unstructured":"Krassas GE, Pontikides N, Kaltsas T, Papadopoulou P, Paunkovic J, Paunkovic N et al (1999) Disturbances of menstruation in hypothyroidism. Clin Endocrinol 50(5):655\u2013659. https:\/\/doi.org\/10.1046\/j.1365-2265.1999.00719.x","journal-title":"Clin Endocrinol"},{"issue":"1","key":"7408_CR37","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/1477-7827-12-89","volume":"12","author":"F Ramezani Tehrani","year":"2014","unstructured":"Ramezani Tehrani F, Rashidi H, Bahri Khomami M, Tohidi M, Azizi F (2014) The prevalence of metabolic disorders in various phenotypes of polycystic ovary syndrome: a community based study in Southwest of Iran. Reprod Biol Endocrinol 12(1):89. https:\/\/doi.org\/10.1186\/1477-7827-12-89","journal-title":"Reprod Biol Endocrinol"},{"issue":"19","key":"7408_CR38","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"323","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Read C (2020) Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. JAMA 323(19):1945\u20131960. https:\/\/doi.org\/10.1001\/jama.2020.4006","journal-title":"JAMA"},{"issue":"3","key":"7408_CR39","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.fertnstert.2012.10.040","volume":"99","author":"F Moro","year":"2013","unstructured":"Moro F, De Simone C, Morciano A, Tropea A, Sagnella F, Palla C et al (2013) Psoriatic patients have an increased risk of polycystic ovary syndrome: results of a cross-sectional analysis. Fertil Steril 99(3):936\u2013942. https:\/\/doi.org\/10.1016\/j.fertnstert.2012.10.040","journal-title":"Fertil Steril"},{"key":"7408_CR40","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ejogrb.2015.06.002","volume":"191","author":"F Moro","year":"2015","unstructured":"Moro F, Tropea A, Scarinci E, Federico A, De Simone C, Caldarola G et al (2015) Psoriasis and polycystic ovary syndrome: a new link in different phenotypes. Eur J Obstet Gynecol Reprod Biol 191:101\u2013105. https:\/\/doi.org\/10.1016\/j.ejogrb.2015.06.002","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"7408_CR41","doi-asserted-by":"publisher","first-page":"889029","DOI":"10.3389\/fendo.2022.889029","volume":"13","author":"Q Wang","year":"2022","unstructured":"Wang Q, Wang H, Li P, Li X, Wang Z, Yan L et al (2022) Association of polycystic ovary syndrome phenotypes with adverse pregnancy outcomes after in-vitro fertilization\/intracytoplasmic sperm injection. Front Endocrinol 13:889029. https:\/\/doi.org\/10.3389\/fendo.2022.889029","journal-title":"Front Endocrinol"},{"issue":"2","key":"7408_CR42","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.rbmo.2018.05.003","volume":"37","author":"M De Vos","year":"2018","unstructured":"De Vos M, Pareyn S, Drakopoulos P, Raimundo JM, Anckaert E, Santos-Ribeiro S et al (2018) Cumulative live birth rates after IVF in patients with polycystic ovaries: phenotype matters. Reprod Biomed Online 37(2):163\u2013171. https:\/\/doi.org\/10.1016\/j.rbmo.2018.05.003","journal-title":"Reprod Biomed Online"},{"issue":"1","key":"7408_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4274\/tjod.90094","volume":"13","author":"S Sel\u00e7uk","year":"2016","unstructured":"Sel\u00e7uk S, \u00d6zkaya E, Eser A, Kuyucu M, Kutlu HT, Devrano\u011flu B et al (2016) Characteristics and outcomes of in vitro fertilization in different phenotypes of polycystic ovary syndrome. Turk J Obstet Gynecol 13(1):1\u20136. https:\/\/doi.org\/10.4274\/tjod.90094","journal-title":"Turk J Obstet Gynecol"},{"issue":"15","key":"7408_CR44","doi-asserted-by":"publisher","first-page":"12026","DOI":"10.3390\/ijms241512026","volume":"24","author":"ANM Yusuf","year":"2023","unstructured":"Yusuf ANM, Amri MF, Ugusman A, Hamid AA, Wahab NA, Mokhtar MH (2023) Hyperandrogenism and its possible effects on endometrial receptivity: a review. Int J Mol Sci 24(15):12026. https:\/\/doi.org\/10.3390\/ijms241512026","journal-title":"Int J Mol Sci"},{"key":"7408_CR45","doi-asserted-by":"publisher","first-page":"766601","DOI":"10.3389\/fendo.2021.766601","volume":"12","author":"J Huang","year":"2021","unstructured":"Huang J, Lin J, Xia L, Tian L, Xu D, Liu P et al (2021) Decreased endometrial thickness is associated with higher risk of neonatal complications in women with polycystic ovary syndrome. Front Endocrinol 12:766601. https:\/\/doi.org\/10.3389\/fendo.2021.766601","journal-title":"Front Endocrinol"},{"issue":"1","key":"7408_CR46","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.fertnstert.2007.02.002","volume":"89","author":"L Engmann","year":"2008","unstructured":"Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C (2008) The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril 89(1):84\u201391. https:\/\/doi.org\/10.1016\/j.fertnstert.2007.02.002","journal-title":"Fertil Steril"},{"issue":"2","key":"7408_CR47","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/s0015-0282(16)56891-5","volume":"62","author":"A Trounson","year":"1994","unstructured":"Trounson A, Wood C, Kausche A (1994) In vitro maturation and the fertilization and developmental competence of oocytes recovered from untreated polycystic ovarian patients. Fertil Steril 62(2):353\u2013362. https:\/\/doi.org\/10.1016\/s0015-0282(16)56891-5","journal-title":"Fertil Steril"},{"issue":"6","key":"7408_CR48","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1093\/humrep\/dez060","volume":"34","author":"VNA Ho","year":"2019","unstructured":"Ho VNA, Braam SC, Pham TD, Mol BW, Vuong LN (2019) The effectiveness and safety of in vitro maturation of oocytes versus in vitro fertilization in women with a high antral follicle count. Hum Reprod 34(6):1055\u20131064. https:\/\/doi.org\/10.1093\/humrep\/dez060","journal-title":"Hum Reprod"},{"key":"7408_CR49","doi-asserted-by":"publisher","unstructured":"Hughes E, Collins J, Vandekerckhove P. Clomiphene citrate for unexplained subfertility in women. Cochrane Database Syst Rev 2000(3):Cd000057. doi: https:\/\/doi.org\/10.1002\/14651858.Cd000057.","DOI":"10.1002\/14651858.Cd000057"},{"issue":"3","key":"7408_CR50","doi-asserted-by":"publisher","first-page":"326","DOI":"10.4103\/ijem.IJEM_30_19","volume":"23","author":"G Sachdeva","year":"2019","unstructured":"Sachdeva G, Gainder S, Suri V, Sachdeva N, Chopra S (2019) Comparison of the different PCOS phenotypes based on clinical metabolic, and hormonal profile, and their response to clomiphene. Indian J Endocrinol Metab 23(3):326\u2013331. https:\/\/doi.org\/10.4103\/ijem.IJEM_30_19","journal-title":"Indian J Endocrinol Metab"},{"issue":"12","key":"7408_CR51","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1111\/j.1471-0528.2009.02347.x","volume":"116","author":"HY Zhang","year":"2009","unstructured":"Zhang HY, Zhu FF, Xiong J, Shi XB, Fu SX (2009) Characteristics of different phenotypes of polycystic ovary syndrome based on the Rotterdam criteria in a large-scale Chinese population. BJOG 116(12):1633\u20131639. https:\/\/doi.org\/10.1111\/j.1471-0528.2009.02347.x","journal-title":"BJOG"},{"key":"7408_CR52","doi-asserted-by":"publisher","DOI":"10.5402\/2012\/569862","volume":"2012","author":"O G\u0142uszak","year":"2012","unstructured":"G\u0142uszak O, Stopi\u0144ska-G\u0142uszak U, Glinicki P, Kapu\u015bci\u0144ska R, Snochowska H, Zgliczy\u0144ski W et al (2012) Phenotype and metabolic disorders in polycystic ovary syndrome. ISRN Endocrinol 2012:569862. https:\/\/doi.org\/10.5402\/2012\/569862","journal-title":"ISRN Endocrinol"},{"issue":"3","key":"7408_CR53","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1097\/aog.0000000000005070","volume":"141","author":"Z Liu","year":"2023","unstructured":"Liu Z, Geng Y, Huang Y, Hu R, Li F, Song Y et al (2023) Letrozole compared with clomiphene citrate for polycystic ovarian syndrome: a systematic review and meta-analysis. Obstet Gynecol 141(3):523\u2013534. https:\/\/doi.org\/10.1097\/aog.0000000000005070","journal-title":"Obstet Gynecol"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-024-07408-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00404-024-07408-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-024-07408-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T07:09:50Z","timestamp":1717398590000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00404-024-07408-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,19]]},"references-count":53,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["7408"],"URL":"https:\/\/doi.org\/10.1007\/s00404-024-07408-2","relation":{},"ISSN":["1432-0711"],"issn-type":[{"value":"1432-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,19]]},"assertion":[{"value":"20 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SHM and VU are employed at Lo.Li. Pharma Srl, Rome (Italy).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}